Last reviewed · How we verify
NCT07081360
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Phase 3 trial testing Neoadjuvant chemotherapy in Pancreas Cancer in 262 participants. Currently enrolling.
20 July 2028
Quick facts
| Lead sponsor | Minia University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 262 |
| Start date | 20 July 2025 |
| Primary completion | 20 July 2028 |
| Estimated completion | 20 August 2028 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Neoadjuvant chemotherapy — full drug profile →
- Upfront Surgery Group
Conditions studied
- Pancreas Cancer — all drugs for Pancreas Cancer →
- Periampullary Cancer — all drugs for Periampullary Cancer →
- Periampullary Carcinoma Resectable — all drugs for Periampullary Carcinoma Resectable →
- Pancreatic Cancer Resectable — all drugs for Pancreatic Cancer Resectable →
Sponsor
Minia University
Who can join
Adults 18 to 75, any sex, with Pancreas Cancer or Periampullary Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesions which are not being detected in early disease status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and periampullary cancer and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC and periampullary Cancer. This randomized controlled trial compares neoadjuvant chemotherapy followed by surgery versus upfront surgery for patients with clearly resectable pancreatic head cancer and periampullary cancer. The study aims to determine if neoadjuvant chemotherapy improves overall survival compared to immediate surgery followed by adjuvant chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07081360
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neoadjuvant chemotherapy
Trials testing the same drug.
- NCT06978322 — Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Canc · recruiting
- NCT06613308 — Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC · not yet recruiting
- NCT06386887 — Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer · NA · recruiting
- NCT06369480 — Prognostic Factors for Survival in Patients With Cholangiocarcinoma · recruiting
- NCT06223763 — SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery · unknown
Other recruiting trials for Pancreas Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting
Other Minia University trials
Trials by the same sponsor.
- NCT07525687 — Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy · NA · not yet recruiting
- NCT07525674 — Vacuum Sealing Drainage (VSD) in Promoting Wound Healing and Reducing Complications in Post-Infected Obstetric and Gynec · NA · not yet recruiting
- NCT07529587 — Laparoscopic Umbilico-uterine Trunk Clipping Approach in the Management of Enhanced Myometrial Vascularity · NA · not yet recruiting
- NCT07500558 — Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for P · NA · not yet recruiting
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07081360 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Minia University
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07081360.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing